CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy

Table 2 Comparison of postoperative data between patients with and without non-alcoholic fatty liver disease after pancreatoduodenectomy

	Non-NAFLD	NAFLD	P value1
	(n = 52)	(n = 30)
BMI (kg/m2)2	20.1 ± 3.5	17.4 ± 2.8	0.004
Total cholesterol (mg/dL)2	159.2 ± 40.4	133.3 ± 36.4	0.011
Triglycerides (mg/dL)2	102.2 ± 36.4	84.9 ± 49.0	0.169
Total protein (g/dL)2	7.0 ± 0.7	6.1 ± 0.7	< 0.001
Albumin (g/dL)2	4.0 ± 0.5	3.1 ± 0.7	< 0.001
Cholinesterase (U/L)2	215.5 ± 78.5	156.9 ± 88.1	0.006
Insulin (μU/mL)2	9.7 ± 9.8	4.1 ± 3.8	0.009
HOMA-IR2	3.1 ± 3.3	1.3 ± 1.2	0.117
HbA1c (%)2	5.5 ± 0.9	5.6 ± 0.9	0.589
ALT2	31.6 ± 18.5	52.0 ± 45.1	0.033
Insulin treatment	12%	27%	0.126

¹P values calculated using the χ² test;

²Measured 6 mo postoperatively. Values represent mean ± SD unless otherwise indicated. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; HOMA-IR: Homeostasis model assessment for insulin resistance; HbA1c: Hemoglobin A1c; ALT: Alanine aminotransferase.